Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose

BIOLOGICAL2 trials

Sponsors

BioNTech SE

Conditions

COVID-19SARS-CoV-2 VirusSevere Acute Respiratory Syndrome Coronavirus 2

Phase 1

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

WithdrawnNCT05630352

BioNTech SECOVID-19

Start: 2025-01-06End: 2026-07-13Updated: 2024-03-18

Phase 3

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

CompletedNCT05543616

BioNTech SECOVID-19, SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2

Start: 2022-09-23End: 2026-07-10Updated: 2026-08-06

Related Papers

Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to &lt;12-Year-Olds

Journal of the Pediatric Infectious Diseases Society2024-06-112 citations

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

Vaccines2024-01-2436 citations

385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2

Open Forum Infectious Diseases2023-11-271 citations

362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to &lt; 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series

Open Forum Infectious Diseases2023-11-27